RxLightning, creator of the industry’s leading platform for streamlining specialty medication access and affordability, is proud to have reached a number of meaningful milestones in the last year – including significant increases in provider users, enrollments completed, and speed-to-therapy – in addition to successful fundraising and award recognitions.

RxLightning launched in 2020 to improve specialty medication enrollment workflows. Since that time, the company has remained committed to building best-in-class access and affordability solutions to benefit those who require accelerated access to life-saving medications. The company has signed on world-renowned manufacturer partners, onboarded thousands of prescribers, and managed tens of thousands of specialty medication enrollments. Notable successes include:

• Since launch, a staggering $3.2 billion in total drug spend has flowed through the RxLightning platform, with 2024 on pace to be a record year.
• In 2023, RxLightning tripled the number of registered providers who can sign medication enrollments within the tool.
• In total, more than 1,200 unique provider organizations – including health systems, clinics, and physician practices – have submitted medication enrollments through the RxLightning portal.
• Core to RxLightning’s success is the speed at which enrollments can be completed. Over the last year, 72% of enrollments were submitted in under 1 day – with the majority being completed in less than 1 hour – greatly accelerating the speed at which patients can receive approval and start their medication regimen.
• Obtaining patient authorization for support services via digital consent was completed between 83% and 91% of the time, depending on the channel (in office signature, email, SMS) – resulting in significant increases in patient engagement opportunities for manufacturers and their hubs, as well as medication initiation boosts.

“Reflecting on the remarkable achievements of the last year, it’s clear that RxLightning’s commitment to transforming specialty medication access and affordability is stronger than ever,” said Julia Regan, CEO and Co-Founder. “Our team’s tireless efforts have propelled us to new levels of success and we are poised to drive outsized innovation and impact in this space.”

In addition to noteworthy user growth and platform usage milestones, RxLightning secured $17.5 million in Series A fundraising from renowned investors – including LRVHealth, McKesson Ventures, Hearst Ventures, and HealthX Ventures – to accelerate growth and new product launches. The company was also recognized for numerous awards, including being named as a PM360 Innovator, KY Inno Fire Award Recipient, Mira Award Winner, and more.

The accomplishments of the last year demonstrate RxLightning’s unwavering dedication to their mission and ongoing innovation. RxLightning remains committed to revolutionizing specialty medication access and affordability and will continue to push the boundaries of what can be achieved in this field. With a focus on growth and evolution, the team will continue to launch novel solutions that drive positive outcomes for patients, providers, and partners alike.

To meet the RxLightning team at the upcoming Asembia 2024 conference, or to learn more about their solutions, please reach out today.

About RxLightning

RxLightning digitizes, automates, and streamlines the historically manual specialty medication onboarding process. With RxLightning, providers can quickly and easily complete patient enrollment for every specialty medication in every therapeutic area, helping reduce paperwork, streamline communication, and accelerate speed-to-therapy. Through the company’s MedAccess Ecosystem, patients, providers, specialty pharmacies, and pharmaceutical manufacturers have insights into each step of the patient onboarding journey. Learn more at rxlightning.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424083891/en/